Since ALK inhibitors and immune check point blockers are also widely used for treatment of NSCLC [8, 38–46], combination and sequential therapies with these agents may improve outcome in patients with advanced NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.